173 related articles for article (PubMed ID: 38612799)
1. Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis.
Illini O; Saalfeld FC; Christopoulos P; Duruisseaux M; Vikström A; Peled N; Demedts I; Dudnik E; Eisert A; Hashemi SMS; Janzic U; Kian W; Mohorcic K; Mohammed S; Silvoniemi M; Rothschild SI; Schulz C; Wesseler C; Addeo A; Armster K; Itchins M; Ivanović M; Kauffmann-Guerrero D; Koivunen J; Kuon J; Pavlakis N; Piet B; Sebastian M; Velthaus-Rusik JL; Wannesson L; Wiesweg M; Wurm R; Albers-Leischner C; Aust DE; Janning M; Fabikan H; Herold S; Klimova A; Loges S; Sharapova Y; Schütz M; Weinlinger C; Valipour A; Overbeck TR; Griesinger F; Jakopovic M; Hochmair MJ; Wermke M
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612799
[TBL] [Abstract][Full Text] [Related]
2. Mobocertinib (TAK-788): A Targeted Inhibitor of
Gonzalvez F; Vincent S; Baker TE; Gould AE; Li S; Wardwell SD; Nadworny S; Ning Y; Zhang S; Huang WS; Hu Y; Li F; Greenfield MT; Zech SG; Das B; Narasimhan NI; Clackson T; Dalgarno D; Shakespeare WC; Fitzgerald M; Chouitar J; Griffin RJ; Liu S; Wong KK; Zhu X; Rivera VM
Cancer Discov; 2021 Jul; 11(7):1672-1687. PubMed ID: 33632773
[TBL] [Abstract][Full Text] [Related]
3. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.
Zhou C; Ramalingam SS; Kim TM; Kim SW; Yang JC; Riely GJ; Mekhail T; Nguyen D; Garcia Campelo MR; Felip E; Vincent S; Jin S; Griffin C; Bunn V; Lin J; Lin HM; Mehta M; Jänne PA
JAMA Oncol; 2021 Dec; 7(12):e214761. PubMed ID: 34647988
[TBL] [Abstract][Full Text] [Related]
4. Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated
Kim TM; Girard N; Leighl NB; Sabari J; Rahhali N; Schioppa CA; Diels J; Sermon J; Chandler C; Kapetanakis V; Jain R; Li T; Sanden SV
Future Oncol; 2024 Mar; 20(8):447-458. PubMed ID: 37882460
[No Abstract] [Full Text] [Related]
5. Mobocertinib: Mechanism of action, clinical, and translational science.
Hanley MJ; Camidge DR; Fram RJ; Gupta N
Clin Transl Sci; 2024 Mar; 17(3):e13766. PubMed ID: 38511563
[TBL] [Abstract][Full Text] [Related]
6. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with
Riely GJ; Neal JW; Camidge DR; Spira AI; Piotrowska Z; Costa DB; Tsao AS; Patel JD; Gadgeel SM; Bazhenova L; Zhu VW; West HL; Mekhail T; Gentzler RD; Nguyen D; Vincent S; Zhang S; Lin J; Bunn V; Jin S; Li S; Jänne PA
Cancer Discov; 2021 Jul; 11(7):1688-1699. PubMed ID: 33632775
[TBL] [Abstract][Full Text] [Related]
7. Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib.
Russell MC; Garelli AM; Reeves DJ
Ann Pharmacother; 2023 Feb; 57(2):198-206. PubMed ID: 35652704
[TBL] [Abstract][Full Text] [Related]
8. The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations.
Hernandez L; Young M
J Manag Care Spec Pharm; 2023 Feb; 29(2):172-186. PubMed ID: 36373869
[No Abstract] [Full Text] [Related]
9. Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.
Ou SI; Lin HM; Hong JL; Yin Y; Jin S; Lin J; Mehta M; Zhang P; Nguyen D; Neal JW
Lung Cancer; 2023 May; 179():107186. PubMed ID: 37075617
[TBL] [Abstract][Full Text] [Related]
10. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC.
Wang K; Du R; Myall NJ; Lewis WE; Uy N; Hong L; Skoulidis F; Byers LA; Tsao A; Cascone T; Pozadzides J; Tu J; Negrao MV; Gibbons DL; Park K; Rinsurongkawong W; Lee JJ; Gandara D; Behl D; Shu CA; Riess JW; Baik C; Wakelee HA; Vaporciyan AA; Heymach JV; Zhang J; Le X
J Thorac Oncol; 2024 Mar; 19(3):500-506. PubMed ID: 38012986
[TBL] [Abstract][Full Text] [Related]
11. Mobocertinib in non-small cell lung cancer.
Liu S; Lowder KE
Drugs Today (Barc); 2022 Nov; 58(11):523-530. PubMed ID: 36422513
[TBL] [Abstract][Full Text] [Related]
12. Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations.
Christopoulos P; Prawitz T; Hong JL; Lin HM; Hernandez L; Jin S; Tan M; Proskorovsky I; Lin J; Zhang P; Patel JD; Ou SI; Thomas M; Stenzinger A
Lung Cancer; 2023 May; 179():107191. PubMed ID: 37058788
[TBL] [Abstract][Full Text] [Related]
13. Positive progress for non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: A novel targeted therapy option.
Zhang W; Dong X
J Oncol Pharm Pract; 2021 Dec; 27(8):2007-2009. PubMed ID: 34569378
[TBL] [Abstract][Full Text] [Related]
14. Real-world efficacy and safety of mobocertinib in
Kian W; Christopoulos P; Remilah AA; Levison E; Dudnik E; Shalata W; Krayim B; Marei R; Yakobson A; Faehling M; Kahala D; Sara Granot I; Levitas D; Peled N; Roisman LC
Front Oncol; 2022; 12():1010311. PubMed ID: 36203432
[TBL] [Abstract][Full Text] [Related]
15. Non-small cell lung cancer with
Kwon CS; Lin HM; Crossland V; Churchill EN; Curran E; Forsythe A; Tomaras D; Ou SI
Curr Med Res Opin; 2022 Aug; 38(8):1341-1350. PubMed ID: 35621011
[TBL] [Abstract][Full Text] [Related]
16. High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial.
Zwierenga F; van Veggel B; Hendriks LEL; Hiltermann TJN; Hiddinga BI; Hijmering Kappelle LBM; Ter Elst A; Hashemi SMS; Dingemans AC; van der Leest C; de Langen AJ; van den Heuvel MM; van der Wekken AJ
Lung Cancer; 2022 Aug; 170():133-140. PubMed ID: 35777160
[TBL] [Abstract][Full Text] [Related]
17. Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for
Yang JC; Zhou C; Jänne PA; Ramalingam SS; Kim TM; Riely GJ; Spira AI; Piotrowska Z; Mekhail T; Garcia Campelo MR; Felip E; Bazhenova L; Jin S; Kaur M; Diderichsen PM; Gupta N; Bunn V; Lin J; N Churchill E; Mehta M; Nguyen D
Expert Rev Anticancer Ther; 2023 Jan; 23(1):95-106. PubMed ID: 36537204
[TBL] [Abstract][Full Text] [Related]
18. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
Park K; Haura EB; Leighl NB; Mitchell P; Shu CA; Girard N; Viteri S; Han JY; Kim SW; Lee CK; Sabari JK; Spira AI; Yang TY; Kim DW; Lee KH; Sanborn RE; Trigo J; Goto K; Lee JS; Yang JC; Govindan R; Bauml JM; Garrido P; Krebs MG; Reckamp KL; Xie J; Curtin JC; Haddish-Berhane N; Roshak A; Millington D; Lorenzini P; Thayu M; Knoblauch RE; Cho BC
J Clin Oncol; 2021 Oct; 39(30):3391-3402. PubMed ID: 34339292
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis.
Yu Z; Xu F; Zou J
Eur J Clin Pharmacol; 2024 Apr; 80(4):505-517. PubMed ID: 38300281
[TBL] [Abstract][Full Text] [Related]
20. EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer.
Leal JL; Alexander M; Itchins M; Wright GM; Kao S; Hughes BGM; Pavlakis N; Clarke S; Gill AJ; Ainsworth H; Solomon B; John T
Clin Lung Cancer; 2021 Nov; 22(6):e859-e869. PubMed ID: 34127383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
